Skip to main content

Table 5 Patient characteristics and implant specification

From: Horizontal augmentation techniques in the mandible: a systematic review

Author Gender Age (y) Inclusion criteria Exclusion criteria Smoking Systemic condition Implant placement after augmentation (mths) Types of implants Mean follow-up (mths)
Amorfini et al. [101] Median 59.5 (32–72) Adult patients; bilateral atrophic edentulous areas in the posterior mandible Systemic diseases affecting the bone metabolism n/a No systemic condition affecting bone metabolism Simultaneous SLActive; Straumann (Basel, Switzerland) 12
Barbu et al. [100] 13 female; 11 male Mean 47.8 (24–71) At least 10-mm residual height, but less than 4.3-mm bucco-lingual dimension Smoking; uncontrolled systemic disease; active periodontal disease Excluded No uncontrolled systemic disease 4 TSV Zimmer Dental Inc (Carlsbad, California, USA) 19.8
Beitlitum et al. [117] 12 female; 3 male Mean 53 (36–68) Mandibular partial edentulism, horizontal bone deficiency that prevented implant placement Presence of uncontrolled periodontal disease involving the residual dentition, an active endodontic condition involving the adjacent teeth > 10cig/d excluded No pregnancy or lactation, bone disease or medication interfering with bone metabolism, history of head and neck radiotherapy, metabolic disorders (eg, uncontrolled diabetes mellitus), immunodeficiency 5–7 6
Di Stefano et al. [104] 3 female; 2 male Mean 45.5 (32–59) Crestal width ≤ 4 mm, crestal height ≥ 10 mm, age > 30 years, controlled oral hygiene and absence of lesions High degree of bruxism; excessive consumption of alcohol; localized radiation therapy of the oral cavity; inflammatory and autoimmune diseases of the oral cavity; and poor oral hygiene > 10cig/d excluded No antineoplastic chemotherapy; blood, liver, and kidney diseases; immunosuppression; corticosteroids and bisphosphonates therapy; pregnancy; 6 XiVE, Dentsply-Friadent, (Mannheim, Germany) 40.5
Nissan et al. [103] 18 female; 3 male Mean 55.7 Patients with a mandibular alveolar ridge requiring a vertical and lateral augmentation of > 3 mm patients in good health Contraindications to implant therapy n/a Healthy 6 Seven; MIS® (Savion, Israel) or Osseotite; Zimmer Biomet 3i (Warsaw, USA) 37 ± 17
Schwartz-Arad et al. [99] 50.3 Edentulous mandibular area with degree of atrophy preventing placement of implants of at least 6 mm in height without the risk of damaging anatomical structures Poor oral hygiene noncompliance 18.2% Exclusion of kidney/liver/connective tissue disease, immunodeficiency, chemotherapy, radiotherapy 5 Screw-Vent and Spline; Zimmer Biomet 3i, (Warsaw, USA) or NobelActive and Replace Select, Nobel Biocare (Goteborg, Sweden) or Implant Direct (Zurich, Switzerland) 39.9 ± 30.9
Silva et al. [105] 15 female; 5 male Mean 51.8 (37–64) Alveolar ridge width and/or height ≤ 6 mm; > 18 yrs. Good oral health, no active periodontal disease, or occlusal problems Compromised oral or general health, pregnancy, alcohol abuse, radiotherapy, bisphosphonates Excluded Good general and mental health 6 TitamaxCM Cortical, Neodent, (Curitiba, Brazil) 31.8 ± 7
Urban et al. [102] 9 female; 3 male 51.4 Horizontal ridge of 4 mm or less, Cawood Howell Class IV, ability to maintain good oral hygiene Smokers, patients with alcohol abuse, periodontal disease Excluded Systemically and periodontally healthy 6.9 Implants with an anodized TiUnite surface (Brånemark System, Nobel Biocare) 20.9 ± 9.5